Last reviewed · How we verify
Application of crisaborole twice daily
Crisaborole, marketed by Cairo University, is a topical treatment applied twice daily, with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of revenue data and key trial results, which may limit its market competitiveness and investor confidence.
At a glance
| Generic name | Application of crisaborole twice daily |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema (PHASE4)
- Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (PHASE4)
- Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis (PHASE3)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PHASE4)
- Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo (PHASE2)
- Crisaborole Ointment for Skin Toxicity Induced by Cetuximab (PHASE2)
- Wearable Skin Sensors to Assess Nocturnal Scratch Behavior
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Application of crisaborole twice daily CI brief — competitive landscape report
- Application of crisaborole twice daily updates RSS · CI watch RSS
- Cairo University portfolio CI